Cognition Therapeutics CEO Issues Letter to Shareholders
Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024 Topline data from...
COVID-19
Gilead Named to Dow Jones Sustainability World Index for Third Consecutive Year
- Gilead Also Included on the Dow Jones Sustainability North America Index; Rankings Reflect Gilead's Ongoing Commitment to Corporate Responsibility...
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of...
ORYZON to Provide Corporate Progress Updates at Several Events in January
7th Sachs Annual Neuroscience Innovation Forum13rd Annual LifeSci Advisors Corporate Access EventBiotech Showcase-2024 42nd Annual J.P. Morgan Healthcare ConferenceInvest Securities...
Pulmocide Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company developing opelconazole for patients suffering...
Optimi Health Granted Precursor Licence To Formulate MDMA And Completes Encapsulation Of 40mg And 60mg Dosage Formats
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi”), a...
BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)
The United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for BBO-8520, a first-in-class...
Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement
SAN DIEGO, CA / ACCESSWIRE / January 2, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified...
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology...
Coherus Announces U.S. Launch of LOQTORZI™
LOQTORZI™ (toripalimab-tpzi) LOQTORZI™ (toripalimab-tpzi) product image – Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all...
Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing
BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024
Presentation will highlight new data of GT-02287 in preclinical models of Parkinson’s diseaseBETHESDA, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) --...
BetterLife Announces Closing of Convertible Debentures For Further Development of BETR-001
VANCOUVER, British Columbia, Jan. 02, 2024 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
SHANGHAI, China, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a...
TechImmune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- TechImmune, LLC., a biotechnology company developing a broad-spectrum, next generation coronavirus...
Glass Lewis Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic
SOUTH SAN FRANCISCO, Calif., Dec. 29, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing...
Hemostemix Clarifies its October 3, 2023 News Release
Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
- Company’s co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding as part of previously announced grant from the US Crohn’s...
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical studyBRAINTREE,...
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 millionYAVNE,...